Elena Tunitsky Bitton, MD
Urogynecology and Reconstructive Pelvic Surgery · Hartford, CTNPI 1043432123
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,475 of the $8,635 with a category attached, or 75.0%. Boston Scientific accounts for 86.3% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $7,326, more than ten times the $238 reported in 2019.
Across 29 payments — averaging $297.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- Coopersurgical, Inc.$525
- Medtronic$253
- AbbVie$142
- Axonics, Inc.$132
- Caldera Medical, Inc$57
- plus $73 from 3 others
What the payments were for
- Consulting fees$6,47575%
- Travel & lodging$99712%
- Food & beverage$1,10613%
- Gifts$571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $7,453 |
| Coopersurgical, Inc. | 2 | $525 |
| Medtronic | 3 | $253 |
| AbbVie(2 entities) | 7 | $142 |
| Axonics, Inc. | 1 | $132 |
| Caldera Medical, Inc | 1 | $57 |
| Applied Medical Resources Corporation | 1 | $31 |
| Baxter Healthcare | 1 | $23 |
| Valencia Technologies Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 124 | $90,148 |
| MyrbetriqMirabegron | 70 | $43,478 |
| Mirabegron ErMirabegron | 19 | $9,142 |
| Estradiol | 61 | $3,235 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 111 | $1,827 |
| Clobetasol Propionate | 20 | $456 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Hartford
- Richard KershenHartford$28K
- Elisabeth SappenfieldHartford$2K
- Nicole WoodHartford$1K
- Noelle WaldschmidtHartford$1K
- Dmitry VolkinWaterford$15K
- Oz HarmanliNew Haven$9K
- Andrea RussoDanbury$8K
- Elisha JacksonNew Haven$4K
- Mark PrestonWaterbury$2K
- Jaclyn MunozNorwalk$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.